[1] Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacological Research. 2005 Feb 1;51(2):85-94.
[2] Kuwabara N, Oyama T, Tomioka D, Ohashi M, Yanagisawa J, Shimizu T, Miyachi H. Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype. Journal of medicinal chemistry. 2012 Jan 10;55(2):893-902.
[3] Grygiel-Górniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications-a review. Nutrition journal. 2014 Dec;13(1):17.
[4] Lazar MA. PPARγ, 10 years later. Biochimie. 2005 Jan 1;87(1):9-13.
[5] Pyper SR, Viswakarma N, Yu S, Reddy JK. PPARα: energy combustion, hypolipidemia, inflammation and cancer. Nuclear receptor signaling. 2010 Jan;8(1):nrs-08002.
[6] Viswakarma N, Jia Y, Bai L, Vluggens A, Borensztajn J, Xu J, Reddy JK. Coactivators in PPAR-regulated gene expression. PPAR research. 2010;2010.
[7] Larsen TM, Toubro S, Astrup A. PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?. International journal of obesity. 2003 Feb;27(2):147.
[8] Badr MZ, Youssef JA, editors. Peroxisome proliferator-activated receptors (PPARs): methods and protocols. Humana Press; 2013.
[9] Youssef JA, Badr MZ. Peroxisome proliferator-activated receptors: discovery and recent advances. Springer Science & Business Media; 2013 Apr 18.
[10] Wang N, Yin R, Liu Y, Mao G, Xi F. Role of peroxisome proliferator-activated receptor-γ in atherosclerosis. Circulation Journal. 2011;75(3):528-35.
[11] Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. Journal of medicinal chemistry. 2000 Feb 24;43(4):527-50.
[12] Balakumar P, Kadian S, Mahadevan N. Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?. Pharmacological Research. 2012 Apr 1;65(4):430-6.
[13] Balakumar P, Arora MK, Singh M. Emerging role of PPAR ligands in the management of diabetic nephropathy. Pharmacological research. 2009 Sep 1;60(3):170-3.
[14] Dickey AS, Pineda VV, Tsunemi T, Liu PP, Miranda HC, Gilmore-Hall SK, Lomas N, Sampat KR, Buttgereit A, Torres MJ, Flores AL. PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically. Nature medicine. 2016 Jan;22(1):37.
[15] Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, Altshuler D, Milstone DS, Mortensen RM, Spiegelman BM, Freeman MW. The role of PPAR-γ in macrophage differentiation and cholesterol uptake. Nature medicine. 2001 Jan;7(1):41.
[16] Yamamoto K, Tamura T, Henmi K, Kuboyama T, Yanagisawa A, Matsubara M, Takahashi Y, Suzuki M, Saito JI, Ueno K, Shuto S. Development of Dihydrodibenzooxepine Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Ligands of a Novel Binding Mode as Anticancer Agents: Effective Mimicry of Chiral Structures by Olefinic E/Z-Isomers. Journal of Medicinal Chemistry. 2018 Oct 23;61(22):10067-83.
[17] Hsu WH, Lee BH, Hsu YW, Pan TM. Inhibition of Th2 cytokine production in T cells by monascin via PPAR-γ activation. Journal of agricultural and food chemistry. 2013 Aug 14;61(34):8126-33.
[18] Li XF, Sun YY, Bao J, Chen X, Li YH, Yang Y, Zhang L, Huang C, Wu BM, Meng XM, Li J. Functional role of PPAR-γ on the proliferation and migration of fibroblast-like synoviocytes in rheumatoid arthritis. Scientific reports. 2017 Oct 4;7(1):12671.
[19] Hsu WH, Lee BH, Pan TM. Monascin attenuates oxidative stress-mediated lung inflammation via peroxisome proliferator-activated receptor-gamma (PPAR-γ) and nuclear factor-erythroid 2 related factor 2 (Nrf-2) modulation. Journal of agricultural and food chemistry. 2014 Jun 3;62(23):5337-44.
[20] Boubia B, Poupardin O, Barth M, Binet J, Peralba P, Mounier L, Jacquier E, Gauthier E, Lepais V, Chatar M, Ferry S. Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. Journal of medicinal chemistry. 2018 Feb 15;61(6):2246-65.
[21] Xu Y, Rito CJ, Etgen GJ, Ardecky RJ, Bean JS, Bensch WR, Bosley JR, Broderick CL, Brooks DA, Dominianni SJ, Hahn PJ. Design and synthesis of α-aryloxy-α-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor α/γ agonists. Journal of medicinal chemistry. 2004 May 6;47(10):2422-5.
[22] Markt P, Petersen RK, Flindt EN, Kristiansen K, Kirchmair J, Spitzer G, Distinto S, Schuster D, Wolber G, Laggner C, Langer T. Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening. Journal of medicinal chemistry. 2008 Sep 27;51(20):6303-17.
[23] Liu K, Xu L, Berger JP, MacNaul KL, Zhou G, Doebber TW, Forrest MJ, Moller DE, Jones AB. Discovery of a novel series of peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes and dyslipidemia. Journal of medicinal chemistry. 2005 Apr 7;48(7):2262-5.
[24] Yu J, Ahn S, Kim HJ, Lee M, Ahn S, Kim J, Jin SH, Lee E, Kim G, Cheong JH, Jacobson KA. Polypharmacology of N 6-(3-Iodobenzyl) adenosine-5′-N-methyluronamide (IB-MECA) and Related A3 Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) γ Partial Agonist and PPARδ Antagonist Activity Suggests Their Antidiabetic Potential. Journal of medicinal chemistry. 2017 Aug 28;60(17):7459-75.
[25] Xu Y, Etgen GJ, Broderick CL, Canada E, Gonzalez I, Lamar J, Montrose-Rafizadeh C, Oldham BA, Osborne JJ, Xie C, Shi Q. Design and synthesis of dual peroxisome proliferator-activated receptors γ and δ agonists as novel euglycemic agents with a reduced weight gain profile. Journal of medicinal chemistry. 2006 Sep 21;49(19):5649-52.
[26] Potterat O, Puder C, Wagner K, Bolek W, Vettermann R, Kauschke SG. Chlorocyclinones A− D, Chlorinated Angucyclinones from Streptomyces sp. Strongly Antagonizing Rosiglitazone-Induced PPAR-γ Activation. Journal of natural products. 2007 Nov 29;70(12):1934-8.
[27] Liu S, Su M, Song SJ, Hong J, Chung HY, Jung JH. An Anti-inflammatory PPAR-γ Agonist from the Jellyfish-derived Fungus Penicillium chrysogenum J08NF-4. Journal of natural products. 2018 Feb 1;81(2):356-63.
[28] Rudolph J, Chen L, Majumdar D, Bullock WH, Burns M, Claus T, Dela Cruz FE, Daly M, Ehrgott FJ, Johnson JS, Livingston JN. Indanylacetic Acid Derivatives Carrying 4-Thiazolyl-phenoxy Tail Groups, a New Class of Potent PPAR α/γ/δ Pan Agonists: Synthesis, Structure− Activity Relationship, and In Vivo Efficacy. Journal of medicinal chemistry. 2007 Mar 8;50(5):984-1000.
[29] Potterat O, Puder C, Wagner K, Bolek W, Vettermann R, Kauschke SG. Chlorocyclinones A− D, Chlorinated Angucyclinones from Streptomyces sp. Strongly Antagonizing Rosiglitazone-Induced PPAR-γ Activation. Journal of natural products. 2007 Nov 29;70(12):1934-8.
[30] Zhang X, Young HA. PPAR and immune system—what do we know?. International immunopharmacology. 2002 Jul 1;2(8):1029-44.
[31] Buscató EL, Blöcher R, Lamers C, Klingler FM, Hahn S, Steinhilber D, Schubert-Zsilavecz M, Proschak E. Design and synthesis of dual modulators of soluble epoxide hydrolase and peroxisome proliferator-activated receptors. Journal of medicinal chemistry. 2012 Nov 19;55(23):10771-5.
[32] Pirat C, Farce A, Lebègue N, Renault N, Furman C, Millet R, Yous S, Speca S, Berthelot P, Desreumaux P, Chavatte P. Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. Journal of medicinal chemistry. 2012 Feb 27;55(9):4027-61.
[33] Li JL, Xiao B, Park M, Yoo ES, Shin S, Hong J, Chung HY, Kim HS, Jung JH. PPAR-γ agonistic metabolites from the ascidian Herdmania momus. Journal of natural products. 2012 Nov 28;75(12):2082-7.
[34] Mahindroo N, Huang CF, Peng YH, Wang CC, Liao CC, Lien TW, Chittimalla SK, Huang WJ, Chai CH, Prakash E, Chen CP. Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities. Journal of medicinal chemistry. 2005 Dec 29;48(26):8194-208.
[35] Nevin DK, Peters MB, Carta G, Fayne D, Lloyd DG. Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds. Journal of medicinal chemistry. 2012 May 24;55(11):4978-89.